Ned Davis Research started coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research report sent to investors on Monday morning, AmericanBankingNews.com reports. The firm issued a neutral rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Roth Capital raised their price target on shares of ACADIA Pharmaceuticals from $20.00 to $23.00 in a research note to investors on Thursday, August 8th. They now have a buy rating on the stock. Separately, analysts at Zacks reiterated an outperform rating on shares of ACADIA Pharmaceuticals in a research note to investors on Wednesday, August 7th. They now have a $26.00 price target on the stock. Finally, analysts at Ladenburg Thalmann raised their price target on shares of ACADIA Pharmaceuticals from $15.00 to $24.00 in a research note to investors on Wednesday, August 7th. They now have a buy rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $23.43.
In other ACADIA Pharmaceuticals news, CFO Thomas H. Aasen unloaded 30,000 shares of the stock on the open market in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $27.87, for a total transaction of $836,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
ACADIA Pharmaceuticals (NASDAQ:ACAD) traded down 12.53% during mid-day trading on Monday, hitting $20.38. The stock had a trading volume of 7,784,311 shares. ACADIA Pharmaceuticals has a 1-year low of $1.80 and a 1-year high of $29.73. The stock has a 50-day moving average of $23.44 and a 200-day moving average of $17.51. The company’s market cap is $1.809 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings data on Tuesday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. The company had revenue of $451.00 million for the quarter, compared to the consensus estimate of $0.45 million. On average, analysts predict that ACADIA Pharmaceuticals will post $-0.44 earnings per share for the current fiscal year.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.